(Albany, US) DelveInsight launched a new report on Ataxia Telangiectasia Pipeline Insights, 2020
Some of the key facts of the report:-
The dynamics of Ataxia-Telangiectasia market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies and incremental healthcare spending across the world. The launch of emerging therapies is expected during the forecast period of 2020–2030.
The pipeline of Ataxia-Telangiectasia is not vigorous. Owing to the positive outcomes of the some of the rare candidates during the developmental stage by key players, such as Ery Del SpA (EryDex System), IntraBio (IB1001), and others, wherein the market size of Ataxia-Telangiectasia is expected to create a significant positive shift.
Ery Del SpA is developing EryDex System, which is in phase III clinical development trial for the patients with Ataxia-Telangiectasia. The EryDex System (EDS) is used to load dexamethasone sodium phosphate (DSP) into autologous erythrocytes, creating the EryDex System end product (EDS-EP). EryDex is a novel, proprietary method of encapsulating a potent steroid, dexamethasone sodium phosphate, in red blood cells allowing for its gradual dephosphorylation and release of dexamethasone in a patient’s circulation for up to 30 days, providing the potential for effective treatment and preventing the unacceptable systemic side effects of oral or intravenous steroid treatment. EryDel has also received Orphan Drug designation in the US and EU, for EryDex System for the treatment of the disease.
IB1001 is being developed by IntraBio which is in phase II clinical developmental trial in patients with Ataxia- Telangiectasia. The US Food and Drug Administration has granted Orphan Drug Designation to IB1000s for the treatment of Ataxia-Telangiectasia (A-T). The company anticipates the trial to be completed by September 2020. The company has evaluated the effect of IB1000s in pre-clinical and compassionate use studies to evaluate the therapeutic value of IB1000s for the treatment of A-T, as well as additional inherited cerebellar ataxias with its collaborators.
There are few companies working to develop potent drugs which show a significant reduction in the patients suffering from Ataxia-Telangiectasia. However, the pipeline for Ataxia-Telangiectasia is not robust creating a high-medical unmet need for better treatment alternatives with prominent emerging drugs in the future. The current scenario also anticipates a positive shift in the market for a study period of 2017–2030.
The launch of the emerging therapies is expected to significantly impact Ataxia Telangiectasia treatment scenario in the upcoming years:- Drugs covered 1. EryDex System 2. IB1001 And many others
The key players in Ataxia Telangiectasia market are: 1. EryDel 2. IntraBio And many others
Request for sample pages:- https://delveinsight.com/sample-request/ataxia-telangiectasia-at-pipeline-insight
Scope of the Report
Report highlights
Table of contents
1. Report Introduction
2. Ataxia Telangiectasia
2.1. Overview
2.2. History
2.3. Ataxia Telangiectasia Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Ataxia Telangiectasia Diagnosis
2.6.1. Diagnostic Guidelines
3. Ataxia Telangiectasia Current Treatment Patterns
3.1. Ataxia Telangiectasia Treatment Guidelines
4. Ataxia Telangiectasia – DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Ataxia Telangiectasia companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Ataxia Telangiectasia Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Ataxia Telangiectasia Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Ataxia Telangiectasia Late Stage Products (Phase-III)
7. Ataxia Telangiectasia Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Ataxia Telangiectasia Discontinued Products
13. Ataxia Telangiectasia Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report?
14. Ataxia Telangiectasia Key Companies
15. Ataxia Telangiectasia Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Ataxia Telangiectasia Unmet Needs
18. Ataxia Telangiectasia Future Perspectives
19. Ataxia Telangiectasia Analyst Review
20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
Related reports :-
Ataxia Telangiectasia Market Insight, Epidemiology and Market Forecast -2030
DelveInsight’ s Ataxia Telangiectasia Market Insights, Epidemiology and Market Forecast – 2030 report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology.
Ataxia Telangiectasia Epidemiology Forecast to 2030
DelveInsight’s Ataxia Telangiectasia Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Ataxia Telangiectasia (AT) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/